LNAI logo

LUNAI BIOWORKS INC

LNAINASDAQ
πŸ† #5397 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track LNAI
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$0
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
16.0x
Expensive
Otter Score
β€”
Insufficient data
No chart data available for LNAI.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.14 – $13.28
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
5.0M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$51,992
Last Q Revenue
$31,050
P/E Ratio
β€”
P/S Ratio
16.0x
EPS (TTM)
$-0.88
Dividend Yield
β€”
Dilution (1yr)
+57.3%
LNAI logo

LUNAI BIOWORKS INC

LNAI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$52K
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$8Mβ–Ό βˆ’57.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5.3Bβ–² +67070.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.6Mβ–² +57.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$375Mβ–² +$378M YoY
StockOtter Β· stockotter.space

About LUNAI BIOWORKS INC

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.